^131I治疗分化型甲状腺癌的副作用的随访研究

为分析和评价＾１３１Ｉ治疗分化型甲状腺癌的副作用，对３４２例分化型甲状腺癌术后接受了＾１３１Ｉ治疗的患者进行了随访研究。服药后急性反应被记录；出院后定期随访血常规，肝肾功能，涎腺功能及有无与＾１３１Ｉ治疗相关的远期副反应。随访时间１～１０年，平均５．４年。结果：放射性甲状腺炎主要发生在吸＾１３１Ｉ率〉３０％的患者；放射性涎腺炎主要发生在吸＾１３１Ｉ率〈３０％的患者；常见的消化道反应：恶心１２．２％

Evaluation of side-effects after 131I-therapy for differentiated thyroid carcinoma]

The purpose of this study was to evaluate the side-effects of differentiated thyroid carcinoma after treatment with 3.7-7.4 GBq of 131I. A total of 342 patients were treated with 131I from May, 1989 to January, 1999. The acute side-effects, the short-term and long-term side-effects were analyzed. The follow-up lasted 1-10 years with an average of 5.4 years. The results showed that thyroiditis occurred predominantly in the patients with a rate of 131I uptake > 30%, whereas sialoadenitis occurred more prevalently in the patients with a rate of 131I uptake < 30% (P < 0.001). The rates of nausea, vomiting, diarrhea and gastralgia were 12.2%, 5.2%, 3.5% and 2.7% respectively. There were no significant changes in the hemogram after treatment, compared against that before treatment. The overall rates of transient platelet abnormalities and leukopenia were 10.4% and 4.0% respectively, but the rates of the abnormalities in the patients with cumulative doses of 131I > 18.5 GBq were significantly higher than those in patients with cumulative doses of 131 I < 18.5 GBq. The lower rate of acute and short-term side-effects and the absence of long-term side-effects in this study indicate that 131I can be safely used to treat differentiated thyroid carcinoma.